Nora-BE Related Published Studies
Well-designed clinical trials related to Nora-BE (Norethindrone)
Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. [2007.09]
Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. [2006.11]
Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. [2006.06]
Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. [2005.11]
Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. [2005.11]
Well-designed clinical trials possibly related to Nora-BE (Norethindrone)
Walking after stroke: what does treadmill training with body weight support add to overground gait training in patients early after stroke?: a single-blind, randomized, controlled trial. [2009.09]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. [2009.08]
Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. [2009.08]
The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. [2009.07]
The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. [2009.07]
Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. [2009.07]
Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.07]
Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy. [2009.07]
Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. [2009.06]
A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. [2009.04]
Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. [2009.04]
The effects of continuous combined oral estradiol and norethisterone on pulsatility index in internal carotid and uterine arteries in early postmenopausal Taiwanese women---a preliminary study. [2009.03]
Effect of dronedarone on cardiovascular events in atrial fibrillation. [2009.02.12]
Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. [2008.11]
Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. [2008.11]
Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study. [2008.11]
The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women. [2008.06]
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. [2008.05]
Testosterone and gonadotropins but not estrogen associated with spatial ability in women suffering from schizophrenia: a double-blind, placebo-controlled study. [2008.05]
Home use of automated external defibrillators for sudden cardiac arrest. [2008.04.24]
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. [2008.04.02]
Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. [2008.03.20]
Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. [2008.03]
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. [2008.03]
Effects of continuous versus cyclical oral contraception: a randomized controlled trial. [2008.02]
Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. [2008.02]
Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. [2008.01.20]
A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. [2008]
Effects of Continuous versus Cyclic Oral Contraception: A Randomized Controlled Trial. [2007.12.04]
Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. [2007.12]
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. [2007.11]
Effects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance. [2007.11]
Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. [2007.11]
Conjugated linoleic acid supplementation alters the 6-mo change in fat oxidation during sleep. [2007.09]
Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. [2007.08]
Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. [2007.07]
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. [2007.07]
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. [2007.06.20]
Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease. [2007.06]
Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. [2007.06]
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. [2007.06]
Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. [2007.04]
Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. [2007.04]
Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration? [2007.04]
Efficacy of citalopram on climacteric symptoms. [2007.03]
Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. [2007.03]
A comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: a randomized, placebo-controlled study. [2007.02]
Effects of postmenopausal hormone replacement therapy on body fat composition. [2007.02]
Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. [2007.02]
Early postmenopausal hormone therapy improves postural balance. [2007.01]
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. [2007.01]
Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. [2007.01]
Monophasic estrogen-progestogen therapy and sexuality in postmenopausal women. [2007]
Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. [2007]
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. [2007]
Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. [2006.12]
Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. [2006.11]
Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. [2006.11]
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. [2006.10.20]
Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. [2006.10]
Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. [2006.10]
Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women. [2006.10]
Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women. [2006.10]
The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. [2006.09.11]
Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. [2006.09]
Tibolone and estradiol plus norethisterone acetate similarly influence endothelium-dependent vasodilatation in healthy postmenopausal women. [2006.08]
Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. [2006.08]
Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition. [2006.07]
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. [2006.07]
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. [2006.07]
Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. [2006.07]
Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. [2006.06]
The effect of low dose hormone therapy on mammographic breast density. [2006.04.20]
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. [2006.04]
The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. [2006.03.20]
Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. [2006.03.20]
Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. [2006.03]
Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. [2006.03]
Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. [2006.02.20]
Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. [2006.02]
Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. [2006.01.20]
Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. [2006.01.20]
Evaluation of mammographic density and (99m)Tc-sestamibi scintimammographic uptake in postmenopausal women on hormone replacement therapy. [2006.01.10]
Is dosage of hormone replacement therapy related with endometrial polyp formation? [2006]
Combined oral contraceptives in women with systemic lupus erythematosus. [2005.12.15]
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. [2005.10.16]
Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. [2005.09]
A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. [2005.08]
A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. [2005.08]
Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. [2005.08]
Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. [2005.08]
The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. [2005.05]
Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. [2005.04.11]
The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. [2005.04]
Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. [2005.04]
|
